Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
The inhibition of 11β-HSD1 has been shown to attenuate the development of type 2 diabetes mellitus, insulin resistance, metabolic syndrome and other diseases mediated by excessive cortisol production.
|
31664610 |
2019 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Therefore, the precise role of 11β-HSD1 in the development of complications associated with the metabolic syndrome has still not been deciphered yet.
|
30796905 |
2019 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
11βHSD1 deficiency enhances myofibroblast activation and promotes initial fibrosis following chemical liver injury; hence, the effects of 11βHSD1 inhibitors on liver injury and repair are likely to be context-dependent and deserve careful scrutiny as these compounds are developed for chronic diseases including metabolic syndrome and dementia.(Hepatology 2018;67:2167-2181).
|
29251794 |
2018 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Knockout mice or a selective inhibitor of 11β-HSD1 improves metabolic syndrome parameters in preclinical models and human clinical trials.
|
30096297 |
2018 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
It has been reported that too much cortisol or overexpression of HSD11B1 induces obesity and the insulin resistance that accompanies metabolic syndrome in rodent adipose tissue.
|
29206210 |
2017 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The association analysis indicated that HSD11B1 rs12086634 TG contributed to an increased risk of both T2D (OR=1.91; 95% CI-1.33-2.76, P=0.0005) and metS (OR=2.37; 95% CI-1.39-4.05, P=0.0015), but HSD11B1 rs846910 AG contributed to an increased risk of T2D (OR=1.62; 95% CI-1.02-2.57, P=0.03) only.
|
28750217 |
2017 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In addition, the protein expression levels of 11β‑HSD1 and DNA damage inducible transcript 3 were detected and the histopathology of important tissues for metabolic syndrome were analyzed.
|
28944856 |
2017 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In addition, pharmacological approaches aimed at reducing aldosterone and GC levels, by means of the inhibition of CYP11B2 (aldosterone synthase) or 11β-HSD1, represent alternative strategies to counter the detrimental effects of excessive levels of corticosteroids, which are often observed in obesity and, more general, in MetS.© 2017 American Physiological Society.Compr Physiol 7:1425-1447, 2017.
|
28915330 |
2017 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
H6PDH and 11β-HSD1 might be the effective and prospective targets for T2DM and metabolic syndromes, based on the interplay between these two enzymes.
|
28751144 |
2017 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
The potential role of 11β-HSD1 in the pathogenesis of the metabolic syndrome has emerged over the past three decades.
|
28765040 |
2017 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Due to its implication in glucocorticoid metabolism, the inhibition of 11β-HSD1 activity has become a dominant strategy for the treatment of metabolic syndrome.
|
26980090 |
2016 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association between seven HSD11B1 gene (encoding 11β-HSD1) polymorphisms and BMI and MetS components in a psychiatric sample treated with potential weight gain-inducing psychotropic drugs (n=478).
|
25751397 |
2015 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Prereceptor activation of glucocorticoid availability in target tissue by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) coupled with hexose-6-phosphate dehydrogenase (H6PDH) is an important mediator of the metabolic syndrome.
|
25389364 |
2015 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Taken together with earlier evidence that non-selective inhibitors of 11βHSD1 enhance insulin sensitivity, these results led to the hypothesis that inhibition of 11βHSD1 might be a promising target for treatment of the metabolic syndrome.
|
24710966 |
2014 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that 11 β -HSD1 activity in liver and adipose tissue is a common mediator of hypertension, hypertriglyceridemia, glucose intolerance, and insulin resistance in metabolic syndrome.
|
23586038 |
2013 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
There was a significant association between the HSD11B1 gene polymorphism (rs12086634) and occurrence of metabolic syndrome compared to controls (P<0.0001).
|
23869418 |
2013 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Finally, we will address the current status of selective 11β-HSD1 inhibitors that are in development and being tested in phase II trials for patients with the metabolic syndrome.
|
23612224 |
2013 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the association of two 11beta-HSD1 gene (HSD11B1) polymorphisms with the metabolic syndrome (MetS) and its characteristics in the Bosnian population.
|
22384521 |
2012 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
GRα and 11β-HSD1 mRNA levels differed among tissues involved in the pathophysiology of metabolic syndrome.
|
23212335 |
2012 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
This positive correlation between obesity markers and 11β-HSD-1 in AA and EA tissues strengthens the evidence that 11β-HSD-1 has a role in metabolic syndrome.
|
23007990 |
2012 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
Hepatic mRNA levels of these genes were higher in obese patients with MS (11β-HSD1, P = 0.002; H6PDH, P = 0.043; GR, P = 0.033; PEPCK, P = 0.032) and positively correlated with the number of clinical characteristics that define the MS.
|
21964795 |
2012 |
Metabolic Syndrome X
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The expression of omental 11β-HSD1 is not increased in severely obese women with metabolic syndrome.
|
22433622 |
2012 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We conclude that, in a population of Southern European Caucasian women with and without PCOS, alleles of HSD11B1 containing the two SNPs rs846910 A and rs12086634 T confer increased 11β-HSD1 expression and activity, which associates with the metabolic syndrome.
|
21622477 |
2011 |
Metabolic Syndrome X
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, HSD11B1 and H6PD polymorphisms may not be associated with type 2 diabetes and metabolic syndrome.
|
21869537 |
2011 |
Metabolic Syndrome X
|
0.300 |
Biomarker
|
disease |
BEFREE |
The employed hierarchical virtual screening protocol not only demonstrates its efficiency, but also provides novel and selective compounds for developing 11β-HSD1 inhibitors to protect against metabolic syndrome.
|
21873057 |
2011 |